New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A
Recently new opportunities are emerging for improving the way patients with Haemophilia A are treated. Among these opportunities, efmoroctocog alfa is a first-in-class recombinant factor VIII-Fc fusion protein (rFVIIIFc) produced by recombinant DNA technology with an extended half-life compared w...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Milano University Press
2022-01-01
|
| Series: | Epidemiology, Biostatistics and Public Health |
| Online Access: | https://riviste.unimi.it/index.php/ebph/article/view/17195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Recently new opportunities are emerging for improving the way patients with Haemophilia A are treated. Among these opportunities, efmoroctocog alfa is a first-in-class recombinant factor VIII-Fc fusion protein (rFVIIIFc) produced by recombinant DNA technology with an extended half-life compared with conventional FVIII preparations. The available evidence coming from an Italian HTA report indicates that efmoroctocog alfa provides an effective alternative to conventional FVIII preparations (including standard rFVIIIs) for the management of Haemophilia A. Moreover, by reducing the frequency of injections required, it has the potential to reduce treatment burden, and hence improve adherence to prophylaxis and patient Quality-of-Life.
|
|---|---|
| ISSN: | 2282-0930 |